Cigna vs Humana
CI and HUM side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and HUM compare
Cigna is the larger company, worth 1.6 times as much as Humana ($78.8B against $49.8B).
Humana grew revenue faster over the last twelve months (18.3% versus 7.8% for Cigna).
Both pay dividends: Cigna yields 2.1% and Humana 0.64%.
Humana scores higher on the StockData Score (9 against 8 for Cigna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | HUM |
|---|---|---|
| Size and price | ||
| Market cap | $78.8B | $49.8B |
| Share price | $298.23 | $414.50 |
| Change, 1 year | −0.30% | 41.6% |
| Change, 5 years | 39.3% | −8.6% |
| Beta (5Y) | 0.33 | 0.46 |
| Employees | 68K | 67K |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 2 | 4 (better) |
| Valuation | ||
| P/E | – | 39.1× |
| P/S | 0.3× (better) | 0.3× |
| P/B | 1.8× (better) | 2.6× |
| EV/EBITDA | 8.2× (better) | 12.0× |
| P/FCF | – | 25.5× |
| FCF yield | – | 3.9% |
| Fair value | – | $295.47 |
| Margin of safety | – | −40.3% |
| Growth | ||
| Revenue growth (TTM) | 7.8% | 18.3% (better) |
| Revenue growth, 5Y average | 11.4% (better) | 10.9% |
| Net income growth (TTM) | – | −18.8% |
| EPS growth (TTM) | – | −18.8% |
| EPS growth, 5Y average | −0.69% (better) | −17.2% |
| Profitability | ||
| Gross margin | 20.6% | – |
| Operating margin | 3.5% (better) | 1.9% |
| Net margin | – | 0.88% |
| FCF margin | – | 1.3% |
| Return on equity | – | 6.8% |
| Return on invested capital | 12.1% | 23.4% (better) |
| Financial health | ||
| Debt / equity | 0.75 | 0.74 (better) |
| Net debt / EBITDA | 1.94 (better) | −2.86 |
| Interest coverage | 7.2× (better) | 3.8× |
| Current ratio | 0.85 | 1.74 (better) |
| Altman Z-score | 2.80 | 4.60 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% (better) | 0.64% |
| Payout ratio | – | 33.6% |
| Years of dividend growth | 5 (better) | 0 |
| Dividend growth, 5Y average | 173% (better) | 7.8% |
| Buyback yield | 1.3% (better) | 0.30% |
| Shareholder yield | 3.4% (better) | 0.94% |
| Ownership | ||
| Held by institutions | 89.9% | 98.6% |
| Held by insiders | 0.41% | 0.33% |
| Insider net buying, 12 months | −$65.8M | $150K (better) |
| Superinvestors holding | 4 (better) | 2 |
| Short interest, % of float | 2.6% | 2.3% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- HUM stock overview
- HUM income statement
- HUM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.